ARCA biopharma

About Us

Science

Business Development

Investors

Newsroom

Links

Careers

Recent News & Events


	ARCA biopharma receives complete response letter from FDA on the Gencaro NDA.
	Data From Gencaro^TM Phase 3 Best Trial At The American College Of Cardiology 58th Annual Scientific Session
	Comparative Analysis Of Four Beta Blocker Trials Presented At The American College Of Cardiology 58TH Annual Scientific Session
	Two Gencaro Posters to be Presented at the American College of Cardiology 58th Annual Scientific Session
	ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer
	ARCA biopharma and Nuvelo Complete Merger Creating Late-Stage Cardiovascular Company
	ARCA biopharma Appoints Derek Cole as Vice President, Investor Relations and Corporate Communications
	ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
	Michael R. Bristow Receives 2008 HFSA Lifetime Achievement Award
	Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
	Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients with Very Favorable Genotypes
	FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure from ARCA biopharma

About

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Broomfield, Colorado.

ARCA biopharma and Nuvelo, Inc. have Merged

On January 27, 2009, ARCA biopharma merged with Nuvelo, Inc., to create a new cardiovascular focused company, with an experienced cardiovascular leadership team significantly increased resources, and a pipeline of drug candidates in development. The new Company is named ARCA biopharma, Inc. and trades on the Nasdaq Global Market under the symbol ABIO. Read about the merger in the press release

Science

ARCA is currently developing Gencaro™ (tradename pending FDA approval) (bucindolol hydrochloride) for the treatment of chronic heart failure. ARCA’s New Drug Application for Gencaro was accepted for filing by the U.S. Food and Drug Administration in September, 2008, and is currently under review by the FDA, with a prescription drug user fee act (PDUFA) date of May 31, 2009.